

Low baseline plasma L-Glutamine concentration identifies hepatocellular carcinoma patients at high risk of developing early gastrointestinal adverse events during sorafenib treatment.

Loreto Boix^{1,2} PhD, Victor Sapena^{1,3}, Esther Samper¹, Álvaro Díaz-González¹ MD PhD, Neus Llarch¹, Gemma Iserte¹, Leonardo G da Fonseca¹ MD, Marco Sanduzzi-Zamparelli¹ MD, Alejandro Forner^{1,2} MD PhD, Jordi Bruix^{1,2} MD PhD, María Reig^{1,2} * MD PhD

Supplementary Table S1: Baseline characteristics of patients who developed GIAEs at 30 days and of those who did not.

Patients, n		All 135	no GIAE at 30 days 121	GIAE at 30 days 14	p-value
Age (years), median [IQR]		62.48 [56.33 to 70.03]	62.45 [56.19 to 69.5]	66.45 [57.86 to 72.39]	0.3
Gender (male), n (%)		117 (86.67)	104 (85.95)	13 (92.86)	0.5
Cirrhosis (Yes), n(%)		131 (97)	117 (96.7)	14 (100)	>0.99
Etiology, n (%)					0.7
	HCV	73 (54.07)	66 (54.55)	7 (50)	
	Alcohol	37 (27.42)	32 (26.45)	5 (35.71)	
	HBV	10 (7.41)	8 (6.61)	2 (14.29)	
	NASH	3 (2.22)	3 (2.48)	0 (0)	
	Co-infection HCV + HBV	2 (1.48)	2 (1.65)	0 (0)	
	Criptogenic	5 (3.7)	5 (4.13)	0 (0)	
	Others	5 (3.7)	5 (4.13)	0 (0)	
Total bilirubin (mg/dL), median [IQR]		1 [0.8 to 1.6]	1 [0.8 to 1.6]	1 [0.7 to 1.3]	0.6
ALT (IU/L), median [IQR]		54 [31 to 95]	54 [31 to 95]	58 [31 to 96]	0.7
AST (UI/L), median [IQR]		65.5 [39 to 99]	67.5 [44 to 101]	54 [36 to 96]	0.4
Alkaline phosphatase (IU/L), median [IQR]		252 [159 - 385]	252 [159 - 392]	252.5 [140 - 310]	0.5
GGT (IU/L), median [IQR]		139 [82 to 289]	137 [79 to 312]	154.5 [109 to 289]	0.5
Albumin (g/L), median [IQR]		39 [35 to 42]	39 [35 to 43]	37 [34 to 40]	0.2
Hemoglobin (g/dL), median [IQR]		13.5 [12 - 14.5]	13.5 [12 - 14.5]	12.95 [11.9 - 14.1]	0.2
Prothrombin time (%), median [IQR]		81 [68 to 89]	81.1 [68 to 90]	80 [68 to 87]	0.9
Hematocrit (%), median [IQR]		41 [37 - 44]	41 [37 - 44]	40 [37 - 42]	0.2
Platelet (count 10 ⁹), median [IQR]		135 [90 - 186]	138 [87 - 188]	113 [99 - 176]	0.6
Leukocyte (count 10 ⁹), median [IQR]		53 [40.8 - 66]	53.8 [41 - 68.9]	43.95 [33.5 - 60.4]	0.1

L-Glutamine (mgr/mL), median [IQR]	19.23 [16.21 to 22.17]	19.68 [16.67 to 22.39]	16.17 [13.03 to 18.03]	<0.01
Child-Pugh Score (Non-cirrhotic** or A / B), n(%)	117 (86.7) / 18 (13.3)	105 (86.8) / 16 (13.2)	12 (85.7) / 2 (14.3)	>0.99
Ascites (No), n (%)	111 (82.22)	20 (16.53)	4 (28.57)	0.3
Encephalopathy (No), n (%)	135 (100)	121 (100)	14 (100)	-
Vascular Invasion (Yes), n (%)	41 (30.37)	39 (32.23)	2 (14.29)	0.2
Extra-hepatic spread (Yes), n (%)	36 (26.67)	87 (71.9)	12 (85.71)	0.3
ECOG-PS (0 / 1), n (%)	118 (87.41) / 17 (12.59)	108 (89.26) / 13 (10.74)	10 (71.43) / 4 (28.57)	0.08
Alpha-fetoprotein (ng/dL), median [IQR]	24 [6 to 207]	26 [6 to 253]	10.5 [6 to 112]	0.5
BCLC stage (A+B / C)*, n (%)	66 (48.89) / 69 (51.11)	56 (46.28) / 65 (53.72)	10 (71.43) / 4 (28.57)	0.09
Previous treatment, n (%)				<0.01
No treatment	42 (31.11)	42 (34.71)	0 (0)	
Liver transplant	3 (2.22)	3 (2.48)	0 (0)	
Ablation	20 (14.81)	20 (16.53)	0 (0)	
Surgery	14 (10.37)	11 (9.09)	3 (21.43)	
Sequential	12 (8.89)	10 (8.26)	2 (14.29)	
Chemoembolization	41 (30.37)	33 (27.27)	8 (57.14)	
Tamoxifen	2 (1.48)	1 (0.83)	1 (7.14)	
Y90	1 (0.74)	1 (0.83)	0 (0)	
Diabetes (Yes), n (%)	46 (34.1)	38 (31.4)	8 (57.1)	0.07
Arterial Hypertension (Yes), n (%)	56 (41.48)	51 (42.15)	5 (35.71)	0.8

*2 BCLC-A patients; ** 4 non-Cirrhotic patients; HCV: Hepatitis C virus; HBV: Hepatitis B virus; NASH: non-alcoholic steatohepatitis; BCLC: Barcelona Clinic Liver Cancer; AST: Aspartate aminotransferase; IU: International Units; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; IQR: Interquartile range.